Journal Watch · ACS Nano · 2026

Engineered Self-Activatable Polymeric Nanozymes Precisely Eradicate Tumor-Associated Intramacrophage Bacteria to Potentiate Immunotherapy Based on Cluster of Differentiation 47 Blockade.

This work presents a strategy for improving CRC immunotherapy through precise targeting of tumor-associated intramacrophage bacteria.

Yu Y, Bai J, Fan J et al.ACS Nano3 min readPharma relevance 40/100

DOI: 10.1021/acsnano.5c15423PMID: 41712924Study type: preclinical (animal / model) study

TL;DR

This work presents a strategy for improving CRC immunotherapy through precise targeting of tumor-associated intramacrophage bacteria.

Key findings

  • Remarkably, intracellular <i>Fn</i> eradication not only reversed the immunosuppressive phenotype of infected macrophages but also triggered paracrine signaling that drove M1 repolarization of neighboring uninfected macrophages.
  • In both xenograft and orthotopic CRC models harboring intracellular <i>Fn</i>, the nanozymes can efficiently eliminate intracellular <i>Fn</i> and systemically remodel the macrophage immune landscape, significantly boosting the therapeutic efficacy of anti-CD47 immunotherapy.
  • This work presents a strategy for improving CRC immunotherapy through precise targeting of tumor-associated intramacrophage bacteria.

What they did

These nanozymes were specifically engulfed by M2-like <i>Fn</i>-infected macrophages via mannose receptor-mediated endocytosis and then activated by overexpressed intracellular hydrogen peroxide to release ferrous ion and AS, which synergistically amplified cytotoxic reactive oxygen species (ROS) generation through Fenton chemistry. Concurrently, AS induced macrophage autophagy, promoting nanozyme-bacteria colocalization in autophagolysosomes to enhance ROS-mediated <i>Fn</i> killing.

Full abstract (original)

Background: Immunotherapy for colorectal cancer (CRC) remains clinically limited by a profoundly immunosuppressive tumor microenvironment. <i>Fusobacterium nucleatum</i> (<i>Fn</i>), which selectively colonizes CRC tumors, drives this immunosuppression by persisting within macrophages and driving their M2 polarization. Here, we engineered a self-activatable polymeric nanozyme comprising ferrocene-bearing glycopolymers with artesunate (AS) payloads to eliminate intramacrophage <i>Fn</i> reservoirs and reprogram the macrophage immune ecosystem.

What they did: These nanozymes were specifically engulfed by M2-like <i>Fn</i>-infected macrophages via mannose receptor-mediated endocytosis and then activated by overexpressed intracellular hydrogen peroxide to release ferrous ion and AS, which synergistically amplified cytotoxic reactive oxygen species (ROS) generation through Fenton chemistry. Concurrently, AS induced macrophage autophagy, promoting nanozyme-bacteria colocalization in autophagolysosomes to enhance ROS-mediated <i>Fn</i> killing.

Results & conclusions: Remarkably, intracellular <i>Fn</i> eradication not only reversed the immunosuppressive phenotype of infected macrophages but also triggered paracrine signaling that drove M1 repolarization of neighboring uninfected macrophages. In both xenograft and orthotopic CRC models harboring intracellular <i>Fn</i>, the nanozymes can efficiently eliminate intracellular <i>Fn</i> and systemically remodel the macrophage immune landscape, significantly boosting the therapeutic efficacy of anti-CD47 immunotherapy. This work presents a strategy for improving CRC immunotherapy through precise targeting of tumor-associated intramacrophage bacteria.

Abstract © the authors / ACS Nano (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acsnano.5c15423 · PubMed 41712924.

Why it matters for pharma & biotech

  • Relevant to Biotechnology & Methods teams tracking ACS Nano for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this ACS Nano study find?

This work presents a strategy for improving CRC immunotherapy through precise targeting of tumor-associated intramacrophage bacteria.

What type of study is this?

It is a preclinical (animal / model) study, published in ACS Nano in 2026. These nanozymes were specifically engulfed by M2-like <i>Fn</i>-infected macrophages via mannose receptor-mediated endocytosis and then activated by overexpressed intracellular hydrogen peroxide to release ferrous ion and AS, which synergistically amplified cytotoxic reactive oxygen species (ROS) generation through Fenton chemistry.

Where can I read the original paper?

The original is at the publisher via DOI 10.1021/acsnano.5c15423. PubMed ID: 41712924. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Yu Y, Bai J, Fan J et al.. Engineered Self-Activatable Polymeric Nanozymes Precisely Eradicate Tumor-Associated Intramacrophage Bacteria to Potentiate Immunotherapy Based on Cluster of Differentiation 47 Blockade.. ACS Nano (2026). DOI: 10.1021/acsnano.5c15423.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/engineered-self-activatable-polymeric-nanozymes-precisely-eradicate-tumo-c15423/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides